AzTrials
AzTrials

Chronic Heart FailurePhase 3ATMOSPHERENCT00853658

Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure

A Phase 3 study testing Enalapril and Aliskiren in people with Chronic Heart Failure, run by Novartis Pharmaceuticals at 806 sites in 44 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Chronic Heart Failure
What is being tested?
Enalapril and Aliskiren
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
7,064 participants
Where
806 sitesin 44 countries
Study dates
Mar 2009to Oct 2015
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients eligible for inclusion in this study had to fulfill all of the following criteria:
  • Patients ≥ 18 years of age, male or female.
  • Patients with a diagnosis of chronic heart failure (NYHA
  • Class II - IV):
  • LVEF ≤ 35% at Visit 1 (local measurement, within the past 6 months assessed by echocardiography, multiple uptake gated acquisition scan (MUGA), computerized tomography(CT) scan, magnetic resonance imaging (MRI) or ventricular angiography)
  • Elevated BNP or NT-proBNP at Visit 1:
Show all 10Show fewer
  • BNP ≥ 150 pg/mL (or BNP ≥ 100 pg/mL and unplanned hospitalization for HF within the last 12 months prior to Visit 1) (according to local measurement). OR NT-proBNP ≥ 600 pg/mL (or NT-proBNP ≥ 400 pg/mL and unplanned hospitalization for HF within the last 12 months prior to Visit 1) (according to local measurement).
  • Patients had to be treated with an ACEI at a stable dose enalapril 10 mg daily at least or any other ACEI, e.g. ramipril, quinapril, lisinopril, fosinopril, perindopril, trandolapril; based on equivalent doses, for at least 4 weeks prior to Visit 1
  • Patients had to be treated with a beta-blocker, unless contraindicated or not tolerated, at a stable dose for at least 4 weeks prior to visit 1 (for patients not on target dose, according to local guidelines, or in absence of that medication, the reason should be documented).
  • Written informed consent to participate in the study and ability to comply with all requirements.

Who cannot join

  • Patients with any of the following were to be excluded from participation in the study:
  • History of hypersensitivity to any of the study drugs including history or allergy to ACEIs as well as known or suspected contraindications to the study drugs or previous history of intolerance to high doses of ACEIs during up- titration process.
  • Patients treated concomitantly with both an ARB and an aldosterone antagonist in addition to study drug at Visit 1.
  • Current acute decompensated HF (defined as an acute exacerbation of a chronic heart failure status manifested by typical signs and symptoms of HF like dyspnea, fatigue etc., that may require IV therapy with diuretics, vasodilators and/or inotropic drugs).
  • Symptomatic hypotension and/or less than 95 mmHg systolic blood pressure (SBP) at Visit 1 and/or less than 90 mmHg SBP at Visit 4.
  • Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or major vascular surgery, percutaneous coronary intervention (PCI) or carotid angioplasty, within the past 3 months prior to Visit 1.
Show all 9Show fewer
  • Coronary or carotid artery disease likely to require surgical or percutaneous intervention within the 6 months after Visit 1.
  • Right heart failure due to severe pulmonary disease.
  • Patients with Diabetes Mellitus.

Trial locations and contacts

806 sites in 44 countries.

806 sites in 44 countries

Germany97 sites

  • Novartis Investigative Site

    Augsburg, 86150

  • Novartis Investigative Site

    Bad Nauheim, 61231

  • Novartis Investigative Site

    Bad Neustadt an der Saale, 97616

  • Novartis Investigative Site

    Bensheim, 64625

  • Novartis Investigative Site

    Berlin, 10367

  • Novartis Investigative Site

    Berlin, 10789

  • Novartis Investigative Site

    Berlin, 12163

  • Novartis Investigative Site

    Berlin, 12351

  • Novartis Investigative Site

    Berlin, 12552

  • Novartis Investigative Site

    Berlin, 13353

  • Novartis Investigative Site

    Berlin, 13405

  • Novartis Investigative Site

    Bochum, 44791

  • Novartis Investigative Site

    Bonn, 53115

  • Novartis Investigative Site

    Bonn, 53127

  • Novartis Investigative Site

    Bonn, 53225

  • Novartis Investigative Site

    Brake, 26919

  • Novartis Investigative Site

    Celle, 29223

  • Novartis Investigative Site

    Chemnitz, 09113

  • Novartis Investigative Site

    Chemnitz, 09116

  • Novartis Investigative Site

    Chemnitz, 09126

  • Novartis Investigative Site

    Coburg, 96450

  • Novartis Investigative Site

    Cologne, 51605

  • Novartis Investigative Site

    Darmstadt, 64283

  • Novartis Investigative Site

    Dessau, 06846

  • Novartis Investigative Site

    Dinkelsbühl, 91550

  • Novartis Investigative Site

    Dorsten, 46282

  • Novartis Investigative Site

    Dortmund, 44137

  • Novartis Investigative Site

    Dresden, 01067

  • Novartis Investigative Site

    Dresden, 01097

  • Novartis Investigative Site

    Dresden, 01219

  • Novartis Investigative Site

    Dresden, 01277

  • Novartis Investigative Site

    Dresden, 01309

  • Novartis Investigative Site

    Duisburg, 47051

  • Novartis Investigative Site

    Duisburg, 47139

  • Novartis Investigative Site

    Düsseldorf, 40593

  • Novartis Investigative Site

    Ebersbach, 02730

  • Novartis Investigative Site

    Erfurt, 99084

  • Novartis Investigative Site

    Erkner, 15537

  • Novartis Investigative Site

    Essen, 45136

  • Novartis Investigative Site

    Essen, 45355

  • Novartis Investigative Site

    Frankfurt, 60594

  • Novartis Investigative Site

    Gotha, 99867

  • Novartis Investigative Site

    Göttingen, Germany, 37073

  • Novartis Investigative Site

    Göttingen, 37075

  • Novartis Investigative Site

    Gütersloh, 33332

  • Novartis Investigative Site

    Halle, 06120

  • Novartis Investigative Site

    Hamburg, 20099

  • Novartis Investigative Site

    Hanover, 30167

  • Novartis Investigative Site

    Hansestadt Salzwedel, 29410

  • Novartis Investigative Site

    Haßloch, 67454

  • Novartis Investigative Site

    Heidelberg, 69115

  • Novartis Investigative Site

    Heidelberg, 69120

  • Novartis Investigative Site

    Heilbronn, 74078

  • Novartis Investigative Site

    Helmbrechts, 95223

  • Novartis Investigative Site

    Heppenheim an der Bergstrasse, 64646

  • Novartis Investigative Site

    Kassel, 34127

  • Novartis Investigative Site

    Kleve, 47533

  • Novartis Investigative Site

    Koblenz, 56068

  • Novartis Investigative Site

    Königsbrück, 01436

  • Novartis Investigative Site

    Köthen, 06366

  • Novartis Investigative Site

    Krefeld, 47798

  • Novartis Investigative Site

    Lambrecht, 67466

  • Novartis Investigative Site

    Landshut, 84034

  • Novartis Investigative Site

    Leipzig, 04177

  • Novartis Investigative Site

    Lichtentanne, 08115

  • Novartis Investigative Site

    Lienen, 49536

  • Novartis Investigative Site

    Loerrach, 79539

  • Novartis Investigative Site

    Ludwigsburg, 71634

  • Novartis Investigative Site

    Lüneburg, 21339

  • Novartis Investigative Site

    Magdeburg, 39110

  • Novartis Investigative Site

    Mainz, 55116

  • Novartis Investigative Site

    Markkleeberg, 04416

  • Novartis Investigative Site

    Mayen, 56727

  • Novartis Investigative Site

    Melsungen, 34212

  • Novartis Investigative Site

    Muehldorf Am Inn, 84453

  • Novartis Investigative Site

    Muehlheim An Der Ruhr, 45468

  • Novartis Investigative Site

    Mülheim, 45468

  • Novartis Investigative Site

    München, 80636

  • Novartis Investigative Site

    Northeim, 37154

  • Novartis Investigative Site

    Nuremberg, 90471

  • Novartis Investigative Site

    Oelde, 59302

  • Novartis Investigative Site

    Oelde, 59303

  • Novartis Investigative Site

    Pirna, 01796

  • Novartis Investigative Site

    Potsdam, 14471

  • Novartis Investigative Site

    Reinfeld, 23858

  • Novartis Investigative Site

    Schwäbisch Hall, 74523

  • Novartis Investigative Site

    Schwalmstadt, 34613

  • Novartis Investigative Site

    Siegen, 57072

  • Novartis Investigative Site

    Solingen, 42651

  • Novartis Investigative Site

    Stade, 21682

  • Novartis Investigative Site

    Stuttgart, 70372

  • Novartis Investigative Site

    Stuttgart, 70378

  • Novartis Investigative Site

    Wedel, 22880

  • Novartis Investigative Site

    Winsen, Lower Saxony, 21423

  • Novartis Investigative Site

    Witten, 58455

  • Novartis Investigative Site

    Würzburg, 97078

  • Novartis Investigative Site

    Zwickau, 08056

Other trials in Germany

United States58 sites

  • Novartis Investigative Site

    Athens, Georgia, 30606

  • Novartis Investigative Site

    Auburn, Maine, 04210

  • Novartis Investigative Site

    Augusta, Georgia, 30904

  • Novartis Investigative Site

    Beverly Hills, California, 90211

  • Novartis Investigative Site

    Boynton Beach, Florida, 33437

  • Novartis Investigative Site

    Charleston, South Carolina, 29403

  • Novartis Investigative Site

    Dallas, Texas, 75226

  • Novartis Investigative Site

    Daytona Beach, Florida, 32117

  • Novartis Investigative Site

    Denver, Colorado, 80218

  • Novartis Investigative Site

    Durham, North Carolina, 27710

  • Novartis Investigative Site

    Elmer, New Jersey, 08318

  • Novartis Investigative Site

    Everett, Washington, 98208

  • Novartis Investigative Site

    Fort Lauderdale, Florida, 33316

  • Novartis Investigative Site

    French Camp, California, 95231

  • Novartis Investigative Site

    Germantown, Tennessee, 38138

  • Novartis Investigative Site

    Gillespie, Illinois, 62033

  • Novartis Investigative Site

    Hollywood, Florida, 33021

  • Novartis Investigative Site

    Hot Springs, Arkansas, 71913

  • Novartis Investigative Site

    Houston, Texas, 77021

  • Novartis Investigative Site

    Houston, Texas, 77030

  • Novartis Investigative Site

    Huntsville, Alabama, 35801

  • Novartis Investigative Site

    Inglewood, California, 90301

  • Novartis Investigative Site

    Jacksonville Beach, Florida, 32050

  • Novartis Investigative Site

    Kirkland, Washington, 98034

  • Novartis Investigative Site

    Laurelton, New York, 11422

  • Novartis Investigative Site

    Lincoln, Nebraska, 68506

  • Novartis Investigative Site

    Little Rock, Arkansas, 72204

  • Novartis Investigative Site

    Little Rock, Arkansas, 72205

  • Novartis Investigative Site

    Littleton, Colorado, 80120

  • Novartis Investigative Site

    Los Angeles, California, 90073

  • Novartis Investigative Site

    Marion, Ohio, 43302

  • Novartis Investigative Site

    Memphis, Tennessee, 38120

  • Novartis Investigative Site

    Metairie, Louisiana, 70006

  • Novartis Investigative Site

    Miami Lakes, Florida, 33014

  • Novartis Investigative Site

    Mobile, Alabama, 36608

  • Novartis Investigative Site

    Mobile, Alabama, 36693

  • Novartis Investigative Site

    Modesto, California, 95355

  • Novartis Investigative Site

    Nashville, Tennessee, 37205

  • Novartis Investigative Site

    Nashville, Tennessee, 37212

  • Novartis Investigative Site

    New Orleans, Louisiana, 70121

  • Novartis Investigative Site

    Northridge, California, 91325

  • Novartis Investigative Site

    Omaha, Nebraska, 68198

  • Novartis Investigative Site

    Orlando, Florida, 32803

  • Novartis Investigative Site

    Pine Bluff, Arkansas, 71603

  • Novartis Investigative Site

    Sacramento, California, 95825

  • Novartis Investigative Site

    San Diego, California, 92123

  • Novartis Investigative Site

    Santa Monica, California, 90404

  • Novartis Investigative Site

    Searcy, Arkansas, 72143

  • Novartis Investigative Site

    Slidell, Louisiana, 70458

  • Novartis Investigative Site

    Southfield, Michigan, 48075

  • Novartis Investigative Site

    St Louis, Missouri, 63110

  • Novartis Investigative Site

    Stony Brook, New York, 11794

  • Novartis Investigative Site

    Topeka, Kansas, 66606

  • Novartis Investigative Site

    Tucson, Arizona, 85723-0001

  • Novartis Investigative Site

    Varnville, South Carolina, 29944

  • Novartis Investigative Site

    Wellington, Florida, 33449

  • Novartis Investigative Site

    Westlake Village, California, 91361

  • Novartis Investigative Site

    Wiliamsville, New York, 14221

Other trials in United States

Italy48 sites

  • Novartis Investigative Site

    Ancona, AN, 60126

  • Novartis Investigative Site

    Arezzo, AR, 52100

  • Novartis Investigative Site

    Bergamo, BG, 24128

  • Novartis Investigative Site

    Bologna, BO, 40138

  • Novartis Investigative Site

    Brescia, BS, 25123

  • Novartis Investigative Site

    Casarano, LE, 73042

  • Novartis Investigative Site

    Castelnuovo di Garfagnana, LU, 55032

  • Novartis Investigative Site

    Cava de' Tirreni, SA, 84013

  • Novartis Investigative Site

    Cecina, LI, 57023

  • Novartis Investigative Site

    Chieti, CH, 66100

  • Novartis Investigative Site

    Cona, FE, 44100

  • Novartis Investigative Site

    Cortona, AR, 52044

  • Novartis Investigative Site

    Cosenza, CS, 87100

  • Novartis Investigative Site

    Cotignola, RA, 48010

  • Novartis Investigative Site

    Florence, FI, 50143

  • Novartis Investigative Site

    Foggia, FG, 71100

  • Novartis Investigative Site

    Forlì, FC, 47100

  • Novartis Investigative Site

    Lumezzane, BS, 25065

  • Novartis Investigative Site

    Massa, MS, 54100

  • Novartis Investigative Site

    Milan, MI, 20132

  • Novartis Investigative Site

    Milan, MI, 20138

  • Novartis Investigative Site

    Montescano, (pv), 27040

  • Novartis Investigative Site

    Orbassano, TO, 10043

  • Novartis Investigative Site

    Palermo, PA, 90127

  • Novartis Investigative Site

    Parma, PR, 43100

  • Novartis Investigative Site

    Passirana Di Rho, MI, 20017

  • Novartis Investigative Site

    Pavia, (pv), 27100

  • Novartis Investigative Site

    Pavia, PV, 27100

  • Novartis Investigative Site

    Perugia, PG, 06129

  • Novartis Investigative Site

    Pieve di Coriano, MN

  • Novartis Investigative Site

    Poggibonsi, SI, 53036

  • Novartis Investigative Site

    Pozzilli, IS, 86077

  • Novartis Investigative Site

    Rimini, RN, 47900

  • Novartis Investigative Site

    Roma, RM, 00169

  • Novartis Investigative Site

    Roma, RM, 00184

  • Novartis Investigative Site

    Roma, RM, 00189

  • Novartis Investigative Site

    San Bonifacio, VR, 37047

  • Novartis Investigative Site

    San Daniele del Friuli, UD, 33038

  • Novartis Investigative Site

    Sarzana, SP, 19038

  • Novartis Investigative Site

    Sassari, SS, 07100

  • Novartis Investigative Site

    Sondalo, SO, 23035

  • Novartis Investigative Site

    Terni, TR, 05100

  • Novartis Investigative Site

    Torino, TO, 10126

  • Novartis Investigative Site

    Tradate, VA, 21049

  • Novartis Investigative Site

    Trieste, TS, 34142

  • Novartis Investigative Site

    Trieste, TS, 34149

  • Novartis Investigative Site

    Udine, UD, 33100

  • Novartis Investigative Site

    Vittorio Veneto, TV, 31029

Other trials in Italy

Japan46 sites

  • Novartis Investigative Site

    Adachi-ku, Tokyo, 120-0006

  • Novartis Investigative Site

    Amagasaki, Hyōgo, 660-8550

  • Novartis Investigative Site

    Bunkyo-ku, Tokyo, 113-8431

  • Novartis Investigative Site

    Bunkyo-ku, Tokyo, 113-8519

  • Novartis Investigative Site

    Bunkyo-ku, Tokyo, 113-8603

  • Novartis Investigative Site

    Bunkyo-ku, Tokyo, 113-8655

  • Novartis Investigative Site

    Chiba, Chiba, 260-8677

  • Novartis Investigative Site

    Chikushino-shi, Fukuoka, 818-8502

  • Novartis Investigative Site

    Fukuoka, Fukuoka, 814-0180

  • Novartis Investigative Site

    Fukushima, Fukushima, 960-8251

  • Novartis Investigative Site

    Hamada, Shimane, 697-8511

  • Novartis Investigative Site

    Higashiibaraki-gun, Ibaraki, 311-3193

  • Novartis Investigative Site

    Hiroshima, Hiroshima, 734-8551

  • Novartis Investigative Site

    Hitachi-Naka, Ibaraki, 312-0057

  • Novartis Investigative Site

    Hōfu, Yamaguchi, 747-8511

  • Novartis Investigative Site

    Iizuka, Fukuoka, 820-8505

  • Novartis Investigative Site

    Inba-gun, Chiba, 270-1694

  • Novartis Investigative Site

    Izumisano, Osaka, 598-8577

  • Novartis Investigative Site

    Kanazawa, Ishikawa-ken, 920-8650

  • Novartis Investigative Site

    Kashihara, Nara, 634-8522

  • Novartis Investigative Site

    Kawasaki, Kanagawa, 210-0852

  • Novartis Investigative Site

    Kita-ku, Osaka, 530-0001

  • Novartis Investigative Site

    Komatsushimachō, Tokushima, 773-8502

  • Novartis Investigative Site

    Kumamoto, Kumamoto, 860-8556

  • Novartis Investigative Site

    Kure, Hiroshima, 737-0023

  • Novartis Investigative Site

    Kurume, Fukuoka, 830-8577

  • Novartis Investigative Site

    Nagasaki, Nagasaki, 850-8555

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 466-8560

  • Novartis Investigative Site

    Ōgaki, Gifu, 503-8502

  • Novartis Investigative Site

    Okayama, Okayama-ken, 702-8055

  • Novartis Investigative Site

    Osaka, Osaka, 545-8586

  • Novartis Investigative Site

    Saga, Saga-ken, 849-8501

  • Novartis Investigative Site

    Sagamihara, Kanagawa, 252-0375

  • Novartis Investigative Site

    Sapporo, Hokkaido, 060-8648

  • Novartis Investigative Site

    Sapporo, Hokkaido, 063-0005

  • Novartis Investigative Site

    Sendai, Miyagi, 980-8574

  • Novartis Investigative Site

    Seto, Aichi-ken, 489-8642

  • Novartis Investigative Site

    Shinjuku-ku, Tokyo, 162-8666

  • Novartis Investigative Site

    Shūnan, Yamaguchi, 745-8522

  • Novartis Investigative Site

    Tokushima, Tokushima, 770-8503

  • Novartis Investigative Site

    Toyama, Toyama, 930-0194

  • Novartis Investigative Site

    Tsukuba, Ibaraki, 305-8576

  • Novartis Investigative Site

    Ube, Yamaguchi, 755-8505

  • Novartis Investigative Site

    Ureshino, Saga-ken, 843-0393

  • Novartis Investigative Site

    Yokohama, Kanagawa, 232-0024

  • Novartis Investigative Site

    Yokosuka, Kanagawa, 238-8567

Other trials in Japan

Russia45 sites

  • Novartis Investigative Site

    Barnaul, 656055

  • Novartis Investigative Site

    Chelyabinsk, 454000

  • Novartis Investigative Site

    Chelyabinsk, 454021

  • Novartis Investigative Site

    Chelyabinsk, 454047

  • Novartis Investigative Site

    Chelyabinsk, 454048

  • Novartis Investigative Site

    Izhevsk, 426009

  • Novartis Investigative Site

    Kirov, 610014

  • Novartis Investigative Site

    Krasnodar, 350063

  • Novartis Investigative Site

    Kursk, 305035

  • Novartis Investigative Site

    Lyubertsy, 140006

  • Novartis Investigative Site

    Moscow, 105229

  • Novartis Investigative Site

    Moscow, 111020

  • Novartis Investigative Site

    Moscow, 111539

  • Novartis Investigative Site

    Moscow, 115432

  • Novartis Investigative Site

    Moscow, 117292

  • Novartis Investigative Site

    Moscow, 119992

  • Novartis Investigative Site

    Moscow, 121359

  • Novartis Investigative Site

    Moscow, 127473

  • Novartis Investigative Site

    Moscow, 129301

  • Novartis Investigative Site

    Moscow

  • Novartis Investigative Site

    Nizhny Novgorod, 603018

  • Novartis Investigative Site

    Novosibirsk, 630047

  • Novartis Investigative Site

    Novosibirsk, 630075

  • Novartis Investigative Site

    Novosibirsk, 630089

  • Novartis Investigative Site

    Omsk, 644018

  • Novartis Investigative Site

    Perm, 614097

  • Novartis Investigative Site

    Pushkin,St-Petersburg, 196601

  • Novartis Investigative Site

    Ryazan, 390026

  • Novartis Investigative Site

    S.-Petersburg, 196247

  • Novartis Investigative Site

    Saint Petersburg, 191119

  • Novartis Investigative Site

    Saint Petersburg, 194044

  • Novartis Investigative Site

    Saint Petersburg, 197022

  • Novartis Investigative Site

    Saint Petersburg, 197341

  • Novartis Investigative Site

    Saint Petersburg, 198013

  • Novartis Investigative Site

    Saratov, 410012

  • Novartis Investigative Site

    Saratov, 410028

  • Novartis Investigative Site

    Tyumen, 625026

  • Novartis Investigative Site

    Volgograd, 400001

  • Novartis Investigative Site

    Volgograd, 400008

  • Novartis Investigative Site

    Voronezh, 394065

  • Novartis Investigative Site

    Yaroslavl, 150000

  • Novartis Investigative Site

    Yaroslavl, 150030

  • Novartis Investigative Site

    Yaroslavl, 150062

  • Novartis Investigative Site

    Yekaterinburg, 620028

  • Novartis Investigative Site

    Yekaterinburg, 620137

Other trials in Russia

India38 sites

  • Novartis Investigative Site

    Ahmedabad, Gujarat, 380 051

  • Novartis Investigative Site

    Bangalore, Karnataka, 560 052

  • Novartis Investigative Site

    Bangalore, Karnataka, 560099

  • Novartis Investigative Site

    Bangalore, 560 034

  • Novartis Investigative Site

    Chennai, Tamil Nadu, 600100

  • Novartis Investigative Site

    Coimbatore, Tamil Nadu, 641014

  • Novartis Investigative Site

    Delhi, New Delhi, 110065

  • Novartis Investigative Site

    Guntur, Andhra Pradesh, 522001

  • Novartis Investigative Site

    Hyderabad, Andhra Pradesh, 500012

  • Novartis Investigative Site

    Hyderabad, Telangana, 500082

  • Novartis Investigative Site

    Hyderabad, 500 063

  • Novartis Investigative Site

    Hyderabad, 500044

  • Novartis Investigative Site

    Jaipur, Rajasthan, 302001

  • Novartis Investigative Site

    Jaipur, Rajasthan, 302024

  • Novartis Investigative Site

    Lucknow, India, 226003

  • Novartis Investigative Site

    Lucknow, Uttar Pradesh, 226005

  • Novartis Investigative Site

    Lucknow, Uttar Pradesh, 226014

  • Novartis Investigative Site

    Madurai, Tamil Nadu, 625107

  • Novartis Investigative Site

    Manipal, Karnataka, 576104

  • Novartis Investigative Site

    Mumbai, India, 400 050

  • Novartis Investigative Site

    Mumbai, Maharashtra, 400 022

  • Novartis Investigative Site

    Nagpur, Maharashtra, 400 008

  • Novartis Investigative Site

    Nagpur, Maharashtra, 400 012

  • Novartis Investigative Site

    Nagpur, Maharashtra, 400012

  • Novartis Investigative Site

    Nagpur, Maharashtra, 440 010

  • Novartis Investigative Site

    Nagpur, Maharashtra, 440010

  • Novartis Investigative Site

    Nagpur, Maharashtra, 440012

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, 110060

  • Novartis Investigative Site

    New Delhi, New Delhi, 110044

  • Novartis Investigative Site

    Noida, India, 201301

  • Novartis Investigative Site

    Pune, Maharashtra, 411 011

  • Novartis Investigative Site

    Pune, Maharashtra, 411 019

  • Novartis Investigative Site

    Pune, Maharashtra, 411 044

  • Novartis Investigative Site

    Pune, Maharashtra, 411004

  • Novartis Investigative Site

    Pune, Maharashtra, 411011

  • Novartis Investigative Site

    Secunderabad, Andhra Pradesh, 500003

  • Novartis Investigative Site

    Trivandrum, Kerala, 695002

  • Novartis Investigative Site

    Vijayawada, Andhra Pradesh, 520 008

Other trials in India

Argentina37 sites

  • Novartis Investigative Site

    Bahía Blanca, Buenos Aires, 8000

  • Novartis Investigative Site

    Buenos Aires, Buenos Aires, C1094AAD

  • Novartis Investigative Site

    Buenos Aires, Buenos Aires, C1428DCO

  • Novartis Investigative Site

    Caba, Buenos Aires, C1180AAX

  • Novartis Investigative Site

    Caba, Buenos Aires, C1408INH

  • Novartis Investigative Site

    Caba, Buenos Aires, C1416DRJ

  • Novartis Investigative Site

    Córdoba, Córdoba Province, X5000AAI

  • Novartis Investigative Site

    Córdoba, Córdoba Province, X5000AVI

  • Novartis Investigative Site

    Córdoba, Córdoba Province, X5000EPU

  • Novartis Investigative Site

    Córdoba, Córdoba Province, X5000EVQ

  • Novartis Investigative Site

    Córdoba, Córdoba Province, X5000FGG

  • Novartis Investigative Site

    Córdoba, Córdoba Province, X5002AOQ

  • Novartis Investigative Site

    Córdoba, Córdoba Province, X5003DCE

  • Novartis Investigative Site

    Córdoba, Córdoba Province, X5004BAL

  • Novartis Investigative Site

    Córdoba, Córdoba Province, X5006IKK

  • Novartis Investigative Site

    Córdoba, Córdoba Province, X5009BSN

  • Novartis Investigative Site

    Córdoba, Córdoba Province, X5022CPU

  • Novartis Investigative Site

    Córdoba, Córdoba Province, X5152HQC

  • Novartis Investigative Site

    Córdoba, Córdoba Province, X5220XAO

  • Novartis Investigative Site

    Coronel Suárez, Buenos Aires, B7540GHD

  • Novartis Investigative Site

    Corrientes, Corrientes Province, W3400CBI

  • Novartis Investigative Site

    Corrientes, Corrientes Province, W3400

  • Novartis Investigative Site

    La Plata, Buenos Aires, 1900

  • Novartis Investigative Site

    Posadas, Misiones Province, N3300AHX

  • Novartis Investigative Site

    Quilmes, Buenos Aires, B1878GEG

  • Novartis Investigative Site

    Ramos Mejía, Buenos Aires, B1704ETD

  • Novartis Investigative Site

    Rosario, Santa Fe Province, S2000CXH

  • Novartis Investigative Site

    Rosario, Santa Fe Province, S2000DFD

  • Novartis Investigative Site

    Rosario, Santa Fe Province, S2000DSV

  • Novartis Investigative Site

    Rosario, Santa Fe Province, S2001ODA

  • Novartis Investigative Site

    Salta, Salta Province, 4400

  • Novartis Investigative Site

    San Isidro, Buenos Aires, B1642DCD

  • Novartis Investigative Site

    San Miguel de Tucumán, San Miguel de Tucuman, T4000ICL

  • Novartis Investigative Site

    San Miguel de Tucumán, Tucumán Province, T4000IFL

  • Novartis Investigative Site

    San Nicolás de los Arroyos, Buenos Aires, B2900DMH

  • Novartis Investigative Site

    Va Allende, Córdoba Province, 5105

  • Novartis Investigative Site

    Villa María, Córdoba Province, X5220XAO

Other trials in Argentina

China33 sites

  • Novartis Investigative Site

    Baotou, 014040

  • Novartis Investigative Site

    Beijing, Beijing Municipality, 100083

  • Novartis Investigative Site

    Beijing, Beijing Municipality, 100088

  • Novartis Investigative Site

    Beijing, Beijing Municipality, 100730

  • Novartis Investigative Site

    Beijing, 100020

  • Novartis Investigative Site

    Beijing, 100028

  • Novartis Investigative Site

    Beijing, 100029

  • Novartis Investigative Site

    Beijing, 100034

  • Novartis Investigative Site

    Beijing, 100044

  • Novartis Investigative Site

    Beijing, 100050

  • Novartis Investigative Site

    Changchun, Jilin, 130021

  • Novartis Investigative Site

    Fuzhou, Fujian, 350001

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510080

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510515

  • Novartis Investigative Site

    Guangzhou, 510080

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310006

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310009

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310013

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310016

  • Novartis Investigative Site

    Jinan, 250012

  • Novartis Investigative Site

    Nanjing, Jiangsu

  • Novartis Investigative Site

    Shanghai, Shanghai Municipality, 200011

  • Novartis Investigative Site

    Shanghai, 200025

  • Novartis Investigative Site

    Shanghai, 200032

  • Novartis Investigative Site

    Shanghai, 200233

  • Novartis Investigative Site

    Shenyang, Liaoning, 110003

  • Novartis Investigative Site

    Shenyang, Liaoning, 110016

  • Novartis Investigative Site

    Shijiazhuang, Hebei, 050000

  • Novartis Investigative Site

    Suzhou, Jiangsu, 215004

  • Novartis Investigative Site

    Tianjin, Tianjin Municipality, 300121

  • Novartis Investigative Site

    Tianjin, 300142

  • Novartis Investigative Site

    Wuhan, Hubei, 430022

  • Novartis Investigative Site

    Xi'an, 710004

Other trials in China

Poland30 sites

  • Novartis Investigative Site

    Bytom, 41-902

  • Novartis Investigative Site

    Chorzów, 41-506

  • Novartis Investigative Site

    Gdansk, 80-180

  • Novartis Investigative Site

    Gdynia, 81-423

  • Novartis Investigative Site

    Gdynia, 81-519

  • Novartis Investigative Site

    Gliwice, 44-100

  • Novartis Investigative Site

    Grodzisk Mazowiecki, 05-825

  • Novartis Investigative Site

    Katowice, 40-040

  • Novartis Investigative Site

    Katowice, 40-084

  • Novartis Investigative Site

    Kłodzko, 57-300

  • Novartis Investigative Site

    Krakow, 30-053

  • Novartis Investigative Site

    Krakow, 31-501

  • Novartis Investigative Site

    Łomża, 18-104

  • Novartis Investigative Site

    Oława, 55-200

  • Novartis Investigative Site

    Opole, 45-706

  • Novartis Investigative Site

    Ostrów Wielkopolski, 63-400

  • Novartis Investigative Site

    Ostrowiec Świętokrzyski, 27-400

  • Novartis Investigative Site

    Piotrkow Trybunalski, 97-300

  • Novartis Investigative Site

    Płock, 09-402

  • Novartis Investigative Site

    Poznan, 61-485

  • Novartis Investigative Site

    Sandomierz, 27-600

  • Novartis Investigative Site

    Tarnów, 33-100

  • Novartis Investigative Site

    Torun, 87-100

  • Novartis Investigative Site

    Warsaw, 03-242

  • Novartis Investigative Site

    Warsaw, 04-628

  • Novartis Investigative Site

    Wroclaw, 50-349

  • Novartis Investigative Site

    Wroclaw, 50-420

  • Novartis Investigative Site

    Wroclaw, 50-981

  • Novartis Investigative Site

    Wroclaw, 52-612

  • Novartis Investigative Site

    Zabrze, 41-800

Other trials in Poland

Denmark22 sites

  • Novartis Investigative Site

    Aalborg, Denmark, DK-9000

  • Novartis Investigative Site

    Århus N, DK-8200

  • Novartis Investigative Site

    Copenhagen, 2100

  • Novartis Investigative Site

    Copenhagen NV, DK-2400

  • Novartis Investigative Site

    Copenhagen S, DK-2300

  • Novartis Investigative Site

    Elsinore, DK-3000

  • Novartis Investigative Site

    Esbjerg, DK-6700

  • Novartis Investigative Site

    Fredericia, 7000

  • Novartis Investigative Site

    Frederiksberg, DK-2000

  • Novartis Investigative Site

    Glostrup Municipality, DK-2600

  • Novartis Investigative Site

    Hellerup, Denmark, DK-2900

  • Novartis Investigative Site

    Hillerød, DK-3400

  • Novartis Investigative Site

    Hjørring, DK-9800

  • Novartis Investigative Site

    Holbæk, DK-4300

  • Novartis Investigative Site

    Hvidovre, Denmark, DK-2650

  • Novartis Investigative Site

    Køge, DK-4600

  • Novartis Investigative Site

    Næstved, DK-4700

  • Novartis Investigative Site

    Odense C, DK-5000

  • Novartis Investigative Site

    Randers NØ, DK-8930

  • Novartis Investigative Site

    Silkeborg, Denmark, 8600

  • Novartis Investigative Site

    Svendborg, DK-5700

  • Novartis Investigative Site

    Viborg, DK-8800

Other trials in Denmark

Slovakia22 sites

  • Novartis Investigative Site

    Bardejov, Slovakia, 085 01

  • Novartis Investigative Site

    Bratislava, Slovak Republic, 812 72

  • Novartis Investigative Site

    Bratislava, Slovak Republic, 826 06

  • Novartis Investigative Site

    Bratislava, 81369

  • Novartis Investigative Site

    Komárno, Slovak Republic, 94575

  • Novartis Investigative Site

    Košice, Slovak Republic, 040 01

  • Novartis Investigative Site

    Košice, Slovak Republic, 04166

  • Novartis Investigative Site

    Košice, Slovakia, 040 01

  • Novartis Investigative Site

    Košice, Slovakia, 04001

  • Novartis Investigative Site

    Levice, Slovak Republic, 93401

  • Novartis Investigative Site

    Lučenec, Slovakia, 98439

  • Novartis Investigative Site

    Nitra, Slovak Republic, 949 01

  • Novartis Investigative Site

    Piešťany, 921 01

  • Novartis Investigative Site

    Považská Bystrica, Slovak Republic, 01701

  • Novartis Investigative Site

    Prešov, Slovak Republic, 08101

  • Novartis Investigative Site

    Prešov, Slovakia, 080 01

  • Novartis Investigative Site

    Stropkov, Slovak Republic, 09101

  • Novartis Investigative Site

    Trebišov, Slovakia, 075 01

  • Novartis Investigative Site

    Trenčín, Slovakia, 911 01

  • Novartis Investigative Site

    Žilina, Slovak Republic, 010 01

  • Novartis Investigative Site

    Žilina, Slovak Republic, 08001

  • Novartis Investigative Site

    Žilina, 012 07

Other trials in Slovakia

Spain22 sites

  • Novartis Investigative Site

    Alicante, Valencia, 03004

  • Novartis Investigative Site

    Badalona, Catalonia, 08916

  • Novartis Investigative Site

    Barcelona, Barcelona, 08041

  • Novartis Investigative Site

    Barcelona, Catalonia, 08035

  • Novartis Investigative Site

    Barcelona, Catalonia, 08036

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, 08907

  • Novartis Investigative Site

    Madrid, Madrid, 28007

  • Novartis Investigative Site

    Madrid, Madrid, 28040

  • Novartis Investigative Site

    Madrid, Madrid, 28041

  • Novartis Investigative Site

    Madrid, Madrid, 28046

  • Novartis Investigative Site

    Madrid, Madrid, 28049

  • Novartis Investigative Site

    Majadahonda, Madrid, 28222

  • Novartis Investigative Site

    Oviedo, Principality of Asturias, 33011

  • Novartis Investigative Site

    Sanlúcar de Barrameda, Andalusia, 11540

  • Novartis Investigative Site

    Santiago de Compostela, Galicia, 15706

  • Novartis Investigative Site

    Seville, Andalusia, 41009

  • Novartis Investigative Site

    Tarragona, Catalonia, 43005

  • Novartis Investigative Site

    Tortosa, Catalonia, 43500

  • Novartis Investigative Site

    Utrera, Andalusia, 41710

  • Novartis Investigative Site

    Valdemoro, Madrid, 28342

  • Novartis Investigative Site

    Valencia, Valencia, 46014

  • Novartis Investigative Site

    Villamartín, Cadiz, 11650

Other trials in Spain

Brazil21 sites

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, 30110-934

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais

  • Novartis Investigative Site

    Brasília, Federal District, 70658-700

  • Novartis Investigative Site

    Campina Grande do Sul, Paraná, 83430-000

  • Novartis Investigative Site

    Campinas, São Paulo, 13020-431

  • Novartis Investigative Site

    Campinas, São Paulo, 13060-904

  • Novartis Investigative Site

    Campinas, São Paulo, 13083-190

  • Novartis Investigative Site

    Caxias do Sul, Rio Grande do Sul, 95070-560

  • Novartis Investigative Site

    Curitiba, Paraná, 80010-030

  • Novartis Investigative Site

    Fortaleza, Ceará, 60864-190

  • Novartis Investigative Site

    Goiânia, Goiás, 74605-050

  • Novartis Investigative Site

    Londrina, Paraná, 86051-990

  • Novartis Investigative Site

    Marília, São Paulo, 17519-030

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90020-090

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90035-903

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90560-030

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90610-000

  • Novartis Investigative Site

    Recife, Pernambuco, 50100-060

  • Novartis Investigative Site

    Rio de Janeiro, Rio de Janeiro, 22240-006

  • Novartis Investigative Site

    São Paulo, São Paulo, 05403-900

  • Novartis Investigative Site

    Tatuí, São Paulo, 18270-170

Other trials in Brazil

Netherlands21 sites

  • Novartis Investigative Site

    Alkmaar, 1815 JD

  • Novartis Investigative Site

    Amsterdam, 1023 NL

  • Novartis Investigative Site

    Amsterdam, 1061 AE

  • Novartis Investigative Site

    Amsterdam, 1091 HA

  • Novartis Investigative Site

    Amsterdam, 1105 AZ

  • Novartis Investigative Site

    Apeldoorn, 7334 DZ

  • Novartis Investigative Site

    Deventer, 7416 SE

  • Novartis Investigative Site

    Dirksland, 3247 BW

  • Novartis Investigative Site

    Enschede, Netherlands, 7513 ER

  • Novartis Investigative Site

    Groningen, 9713 GZ

  • Novartis Investigative Site

    Haarlem, 2035 RC

  • Novartis Investigative Site

    Heerlen, 6419 PC

  • Novartis Investigative Site

    Leeuwarden, 8934 AD

  • Novartis Investigative Site

    Leiderdorp, NL-2353 GA

  • Novartis Investigative Site

    Meppel, 7943 KA

  • Novartis Investigative Site

    Rotterdam, 3045 PM

  • Novartis Investigative Site

    Rotterdam, 3083 AN

  • Novartis Investigative Site

    Venlo, 5912 BL

  • Novartis Investigative Site

    Wildervank, 9648 BE

  • Novartis Investigative Site

    Zutphen, Netherlands, 7207 AE

  • Novartis Investigative Site

    Zwolle, 8011 JW

Other trials in Netherlands

Sweden21 sites

  • Novartis Investigative Site

    Falun, 791 82

  • Novartis Investigative Site

    Gothenburg, 416 85

  • Novartis Investigative Site

    Karlstad, 681 85

  • Novartis Investigative Site

    Linköping, 581 85

  • Novartis Investigative Site

    Lund, SE-222 21

  • Novartis Investigative Site

    Malmö, Sweden, SE 211 36

  • Novartis Investigative Site

    Malmö, 205 02

  • Novartis Investigative Site

    Malmö, 214 22

  • Novartis Investigative Site

    Mölndal, 431 80

  • Novartis Investigative Site

    Nässjö, Sweden, SE 571 31

  • Novartis Investigative Site

    Örebro, 701 85

  • Novartis Investigative Site

    Skellefteå, 931 86

  • Novartis Investigative Site

    Stockholm, 111 57

  • Novartis Investigative Site

    Stockholm, 112 81

  • Novartis Investigative Site

    Stockholm, 17176

  • Novartis Investigative Site

    Stockholm, SE-111 35

  • Novartis Investigative Site

    Sundsvall, 851 86

  • Novartis Investigative Site

    Sundsvall, 852 31

  • Novartis Investigative Site

    Umeå, 901 85

  • Novartis Investigative Site

    Uppsala, SE-751 85

  • Novartis Investigative Site

    Västerås, s-721 89

Other trials in Sweden

Romania18 sites

  • Novartis Investigative Site

    Baia Mare, 430123

  • Novartis Investigative Site

    Brasov, Romania, 500281

  • Novartis Investigative Site

    Brasov, Romania, 500427

  • Novartis Investigative Site

    Bucharest, District 1, 012051

  • Novartis Investigative Site

    Bucharest, District 1, 012064

  • Novartis Investigative Site

    Bucharest, District 2, 021705

  • Novartis Investigative Site

    Cluj-Napoca, 400006

  • Novartis Investigative Site

    Cluj-Napoca, 400347

  • Novartis Investigative Site

    Iași, Jud Iasi, 700005

  • Novartis Investigative Site

    Iași, Jud. Iasi, 700506

  • Novartis Investigative Site

    Iași, 700547

  • Novartis Investigative Site

    Oradea, Romania, 410169

  • Novartis Investigative Site

    Piteşti, 110114

  • Novartis Investigative Site

    Târgu Mureş, Jud Mures, 540043

  • Novartis Investigative Site

    Târgu Mureş, Mureș County, 540136

  • Novartis Investigative Site

    Târgu Mureş, 540096

  • Novartis Investigative Site

    Timișoara, Romania, 300736

  • Novartis Investigative Site

    Timișoara, 300310

Other trials in Romania

Czechia17 sites

  • Novartis Investigative Site

    Benešov, Czech Republic, 25601

  • Novartis Investigative Site

    Brno, Czech Republic, 60200

  • Novartis Investigative Site

    Český Krumlov, Czech Republic, 381 01

  • Novartis Investigative Site

    Jindřichův Hradec, Czech Republic, 377 01

  • Novartis Investigative Site

    Kolín, Czech Republic, 280 02

  • Novartis Investigative Site

    Kroměříž, Czech Republic, 767 01

  • Novartis Investigative Site

    Louny, Czech Republic, 440 01

  • Novartis Investigative Site

    Louny, Czech Republic

  • Novartis Investigative Site

    Mariánské Lázně, 353 01

  • Novartis Investigative Site

    Ostrava, Czech Republic, 70200

  • Novartis Investigative Site

    Pilsen, Czech Republic, 323 00

  • Novartis Investigative Site

    Prague, Czech Republic, 148 00

  • Novartis Investigative Site

    Prague, Czech Republic

  • Novartis Investigative Site

    Prague, 128 08

  • Novartis Investigative Site

    Pribram VIII, 261 01

  • Novartis Investigative Site

    Teplice, Czech Republic, 415 01

  • Novartis Investigative Site

    Vyškov, Czech Republic, 68001

Other trials in Czechia

United Kingdom16 sites

  • Novartis Investigative Site

    Addlestone, Surrey, KT15 2BH

  • Novartis Investigative Site

    Cardiff, CF5 4AD

  • Novartis Investigative Site

    Chesterfield, S44 5BL

  • Novartis Investigative Site

    Chichester, West Sussex, PO19 6SE

  • Novartis Investigative Site

    Colchester, CO4 5JL

  • Novartis Investigative Site

    Dafen, Llanelli, SA14 8QF

  • Novartis Investigative Site

    East Yorkshire, HU16 5JQ

  • Novartis Investigative Site

    Glasgow, G51 4TF

  • Novartis Investigative Site

    Leicester, Leicestershire, LE3 9QP

  • Novartis Investigative Site

    Liverpool, L14 3PE

  • Novartis Investigative Site

    London, SE1 7EH

  • Novartis Investigative Site

    London, SW17 0RE

  • Novartis Investigative Site

    Manchester, M23 9LT

  • Novartis Investigative Site

    Southampton, SO16 6YD

  • Novartis Investigative Site

    Swindon, SN3 6BB

  • Novartis Investigative Site

    Worthing, West Sussex, BN11 2DH

Other trials in United Kingdom

France13 sites

  • Novartis Investigative Site

    Albi, 81013

  • Novartis Investigative Site

    Angers, 49000

  • Novartis Investigative Site

    Bécon-les-Granits, 49370

  • Novartis Investigative Site

    Clichy, 92110

  • Novartis Investigative Site

    Dijon, 21079

  • Novartis Investigative Site

    Grenoble, 38043

  • Novartis Investigative Site

    Marseille, 13385

  • Novartis Investigative Site

    Marseille, 13915

  • Novartis Investigative Site

    Paris, 75013

  • Novartis Investigative Site

    Paris, 75571

  • Novartis Investigative Site

    Pessac, 33604

  • Novartis Investigative Site

    Saint-Etienne, 42055

  • Novartis Investigative Site

    Vandœuvre-lès-Nancy, 54511

Other trials in France

Belgium12 sites

  • Novartis Investigative Site

    Anderlecht, 1070

  • Novartis Investigative Site

    Bruges, 8000

  • Novartis Investigative Site

    Brussels, Belgium, 1180

  • Novartis Investigative Site

    Brussels, 1200

  • Novartis Investigative Site

    De Pinte, 9840

  • Novartis Investigative Site

    Eupen, 4700

  • Novartis Investigative Site

    Genk, 3600

  • Novartis Investigative Site

    Huy, 4500

  • Novartis Investigative Site

    Ieper, 8900

  • Novartis Investigative Site

    Leuven, 3000

  • Novartis Investigative Site

    Liège, 4000

  • Novartis Investigative Site

    Turnhout, 2300

Other trials in Belgium

South Korea12 sites

  • Novartis Investigative Site

    Busan, 602-715

  • Novartis Investigative Site

    Daejeon, 302-241

  • Novartis Investigative Site

    Gwangju, Gwangju, 501-757

  • Novartis Investigative Site

    Incheon, 405-760

  • Novartis Investigative Site

    Seongnam-si, Gyeonggi-do, 13620

  • Novartis Investigative Site

    Seoul, Korea, 03080

  • Novartis Investigative Site

    Seoul, Korea, 03722

  • Novartis Investigative Site

    Seoul, Korea, 05505

  • Novartis Investigative Site

    Seoul, Korea, 06351

  • Novartis Investigative Site

    Seoul, Korea, 152-703

  • Novartis Investigative Site

    Seoul, 143-729

  • Novartis Investigative Site

    Taegu, 700 - 721

Other trials in South Korea

Australia11 sites

  • Novartis Investigative Site

    Auchenflower, Queensland, 4066

  • Novartis Investigative Site

    Bedford Park, South Australia, 5042

  • Novartis Investigative Site

    Canberra, Australian Capital Territory, 2605

  • Novartis Investigative Site

    Darlinghurst, New South Wales, 2010

  • Novartis Investigative Site

    Geelong, Victoria, 3220

  • Novartis Investigative Site

    Kingswood, New South Wales, 2747

  • Novartis Investigative Site

    Launceston, Tasmania, 7250

  • Novartis Investigative Site

    Prahran, Victoria, 3181

  • Novartis Investigative Site

    Wollongong, New South Wales, 2500

  • Novartis Investigative Site

    Woolloongabba, Queensland, 4101

  • Novartis Investigative Site

    Wooloongabba, Queensland, 4102

Other trials in Australia

Colombia11 sites

  • Novartis Investigative Site

    Baranquilla, Atlántico

  • Novartis Investigative Site

    Barranquilla, Atlántico

  • Novartis Investigative Site

    Barranquilla

  • Novartis Investigative Site

    Bogota, Cundinamarca, 111411

  • Novartis Investigative Site

    Bogotá, Cundinamarca, 110111

  • Novartis Investigative Site

    Bogotá, 00000

  • Novartis Investigative Site

    Bogotá

  • Novartis Investigative Site

    Cartagena, Departamento de Bolívar

  • Novartis Investigative Site

    Florida Blanca

  • Novartis Investigative Site

    Medellín, Antioquia

  • Novartis Investigative Site

    Medellín

Other trials in Colombia

Canada10 sites

  • Novartis Investigative Site

    Brampton, Ontario, L6Z 4N5

  • Novartis Investigative Site

    Calgary, Alberta, T2N 4Z6

  • Novartis Investigative Site

    Cambridge, Ontario, N1R 6V6

  • Novartis Investigative Site

    Joliette, Quebec, J6E 6J2

  • Novartis Investigative Site

    Montreal, Quebec, H1T 1C8

  • Novartis Investigative Site

    Montreal, Quebec, H1T 3Y7

  • Novartis Investigative Site

    Ottawa, Ontario, K1Y 4W7

  • Novartis Investigative Site

    Québec, Quebec, G1J 1Z6

  • Novartis Investigative Site

    Saint John, New Brunswick, E2L 4L2

  • Novartis Investigative Site

    Sainte-Foy, Quebec, G1V 4G5

Other trials in Canada

Peru10 sites

  • Novartis Investigative Site

    Bellavista, Lima region, Callao 02

  • Novartis Investigative Site

    Chiclayo, Lambayeque

  • Novartis Investigative Site

    Jesus Maria, Lima region, 11

  • Novartis Investigative Site

    Lima, Lima Province, Lima 39

  • Novartis Investigative Site

    Lima Cercado, Lima region, 01

  • Novartis Investigative Site

    Miraflores, Lima region, 18

  • Novartis Investigative Site

    San Borja, Lima region, 41

  • Novartis Investigative Site

    San Isidro, Lima region, 27

  • Novartis Investigative Site

    San Juan de Miraflores, Lima region, 29

  • Novartis Investigative Site

    Trujillo, La Libertad

Other trials in Peru

Portugal10 sites

  • Novartis Investigative Site

    Amadora, Portugal, 2720-276

  • Novartis Investigative Site

    Aveiro, 3814-501

  • Novartis Investigative Site

    Carnaxide, Portugal, 2799-523

  • Novartis Investigative Site

    Coimbra, Portugal, 3000-075

  • Novartis Investigative Site

    Faro, 8000-386

  • Novartis Investigative Site

    Lisbon, Portugal, 1495-005

  • Novartis Investigative Site

    Lisbon, Portugal, 1600-190

  • Novartis Investigative Site

    Lisbon, Portugal, 1769-001

  • Novartis Investigative Site

    Penafiel, Portugal, 4564-007

  • Novartis Investigative Site

    Porto, Portugal, 4200-319

Other trials in Portugal

Turkey (Türkiye)10 sites

  • Novartis Investigative Site

    Ankara, 06100

  • Novartis Investigative Site

    Aydin, Turkey, 09100

  • Novartis Investigative Site

    Balcova / Izmir, 35340

  • Novartis Investigative Site

    Etlik / Ankara, 06018

  • Novartis Investigative Site

    Fatih / Istanbul, 34098

  • Novartis Investigative Site

    Istanbul, Turkey, 34304

  • Novartis Investigative Site

    Izmir, Turkey, 35040

  • Novartis Investigative Site

    Kinikli / Denizli, 20070

  • Novartis Investigative Site

    Kocaeli, 41380

  • Novartis Investigative Site

    Sivas, 58140

Other trials in Turkey (Türkiye)

Austria9 sites

  • Novartis Investigative Site

    Graz, Austria, A-8036

  • Novartis Investigative Site

    Innsbruck, Tyrol, 6020

  • Novartis Investigative Site

    Linz, 4010

  • Novartis Investigative Site

    Linz, A-4010

  • Novartis Investigative Site

    Salzburg, A-5020

  • Novartis Investigative Site

    Vienna, 1030

  • Novartis Investigative Site

    Vienna, 1140

  • Novartis Investigative Site

    Vienna, A-1090

  • Novartis Investigative Site

    Vienna, A-1160

Other trials in Austria

Switzerland9 sites

  • Novartis Investigative Site

    Basel, 4031

  • Novartis Investigative Site

    Bellinzona, 6500

  • Novartis Investigative Site

    Bern, 3010

  • Novartis Investigative Site

    Biel, 2500

  • Novartis Investigative Site

    Bruderholz, 4101

  • Novartis Investigative Site

    Lugano, 6903

  • Novartis Investigative Site

    Olten, 4600

  • Novartis Investigative Site

    Winterthur, 8401

  • Novartis Investigative Site

    Zurich, 8091

Other trials in Switzerland

Venezuela9 sites

  • Novartis Investigative Site

    Barcelona, Anzoátegui, 6001

  • Novartis Investigative Site

    Caracas, Distrito Federal, 1010

  • Novartis Investigative Site

    Caracas, Distrito Federal, 1040

  • Novartis Investigative Site

    Caracas, Distrito Federal, 1060

  • Novartis Investigative Site

    Caracas, Miranda, 1061

  • Novartis Investigative Site

    Cumaná, Sucre, 6101

  • Novartis Investigative Site

    Maracaibo, Zulia, 4011

  • Novartis Investigative Site

    Puerto Ordaz and San Felix, Bolívar, 8050

  • Novartis Investigative Site

    Valencia, Edo. Carabobo, 2001

Other trials in Venezuela

Greece8 sites

  • Novartis Investigative Site

    Athens, Greece, 124 62

  • Novartis Investigative Site

    Athens, Greece, GR 11527

  • Novartis Investigative Site

    Athens, GR, 115 27

  • Novartis Investigative Site

    Athens, 115 28

  • Novartis Investigative Site

    Chios, 82100

  • Novartis Investigative Site

    Edessa, 58200

  • Novartis Investigative Site

    Thessaloniki, GR, 546 36

  • Novartis Investigative Site

    Thessaloniki, GR, 570 10

Other trials in Greece

Mexico8 sites

  • Novartis Investigative Site

    Aguascalientes, Aguascalientes, 20230

  • Novartis Investigative Site

    Culiacán, Sinaloa, CP:83230

  • Novartis Investigative Site

    Guadalajara, Jalisco, 44600

  • Novartis Investigative Site

    Monterrey, Nuevo León, 64060

  • Novartis Investigative Site

    Monterrey, Nuevo León, 64710

  • Novartis Investigative Site

    Querétaro City, Querétaro, 76000

  • Novartis Investigative Site

    San Luis Potosí City, San Luis Potosí, 78200

  • Novartis Investigative Site

    Zapopan, Jalisco, 45200

Other trials in Mexico

Taiwan8 sites

  • Novartis Investigative Site

    Kaohsiung City, 807

  • Novartis Investigative Site

    Linkou District, 33305

  • Novartis Investigative Site

    Niaosong Township, Taiwan, 83301

  • Novartis Investigative Site

    Taichung, Taiwan, 40447

  • Novartis Investigative Site

    Tainan, Taiwan ROC, 70403

  • Novartis Investigative Site

    Taipei, Taiwan, 10002

  • Novartis Investigative Site

    Taipei, Taiwan, 104

  • Novartis Investigative Site

    Yongkang District, Tainan, 71004

Other trials in Taiwan

South Africa7 sites

  • Novartis Investigative Site

    Benoni

  • Novartis Investigative Site

    Boksburg

  • Novartis Investigative Site

    Centurion, 4001

  • Novartis Investigative Site

    Johannesburg, 2157

  • Novartis Investigative Site

    Soweto, Gauteng, 2013

  • Novartis Investigative Site

    Western Cape, 7130

  • Novartis Investigative Site

    Worcester, 6850

Other trials in South Africa

Finland5 sites

  • Novartis Investigative Site

    Ekenäs, 10600

  • Novartis Investigative Site

    Hyvinkää, FIN-05850

  • Novartis Investigative Site

    Jyväskylä, FIN-40620

  • Novartis Investigative Site

    Seinäjoki, Finland, 60200

  • Novartis Investigative Site

    Turku, FIN-20520

Other trials in Finland

Costa Rica4 sites

  • Novartis Investigative Site

    Alajuela, Costa Rica

  • Novartis Investigative Site

    Guadalupe, San Jose, Costa Rica, 3184-1000

  • Novartis Investigative Site

    San José, Costa Rica, 1307-1000

  • Novartis Investigative Site

    San José, Costa Rica, 272-1225

Other trials in Costa Rica

Estonia4 sites

  • Novartis Investigative Site

    Pärnu, 80010

  • Novartis Investigative Site

    Tallinn, Estonia, 10138

  • Novartis Investigative Site

    Tallinn, 13419

  • Novartis Investigative Site

    Tartu, 51014

Other trials in Estonia

Ireland4 sites

  • Novartis Investigative Site

    Co Dublin, Ireland

  • Novartis Investigative Site

    Dublin, 9

  • Novartis Investigative Site

    Dublin

  • Novartis Investigative Site

    Galway, Ireland

Other trials in Ireland

Latvia4 sites

  • Novartis Investigative Site

    Daugavpils, LV-5401

  • Novartis Investigative Site

    Riga, 1012

  • Novartis Investigative Site

    Riga, LV-1012

  • Novartis Investigative Site

    Riga, LV-1038

Other trials in Latvia

Lithuania4 sites

  • Novartis Investigative Site

    Kaunas, LTU, 50009

  • Novartis Investigative Site

    Kaunas, LT-47144

  • Novartis Investigative Site

    Klaipėda, LT-92288

  • Novartis Investigative Site

    Vilnius, 08661

Other trials in Lithuania

Thailand4 sites

  • Novartis Investigative Site

    Bangkok, 10330

  • Novartis Investigative Site

    Bangkok, 10400

  • Novartis Investigative Site

    Bangkok, 10700

  • Novartis Investigative Site

    Chiang Mai, 50200

Other trials in Thailand

Norway3 sites

  • Novartis Investigative Site

    Oslo, 0514

  • Novartis Investigative Site

    Tønsberg, 3116

  • Novartis Investigative Site

    Trondheim, 7006

Other trials in Norway

Puerto Rico3 sites

  • Novartis Investigative Site

    Humacao, 00791

  • Novartis Investigative Site

    Ponce, 00717

  • Novartis Investigative Site

    San Juan, 00936-6528

Other trials in Puerto Rico

Dominican Republic2 sites

  • Novartis Investigative Site

    San Cristobal, San Cristóbal

  • Novartis Investigative Site

    Santo Domingo, Republica Dominicana

Other trials in Dominican Republic

About this study

Official title: A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in Patients With Chronic Heart Failure (NYHA Class II - IV). The Study is Also Known as Aliskiren Trial of Minimizing OutcomeS in Patients With HEart Failure (ATMOSPHERE).

The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV.

Being tested
Enalapril, Aliskiren
Keywords
Chronic Heart Failure, Cardiovascular death, CHF hospitalization, morbi-mortality trial, outcome study, endpoint driven, plasma renin activity, renin angiotensin aldosterone system, direct renin inhibitors, BNP, KCCQ, eGFR, (NYHA class II to IV) with elevated, BNP and reduced LVEF

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EnalaprilDrug

    Enalapril 10 mg film-coated tablet and administered orally.

  • AliskirenDrug

    Also called SPP100

    Aliskiren 150 mg titrated to 300 mg film-coated tablet and administered orally.

Study groups in NCT00853658
Study groupRoleWhat they receive
Combination Aliskiren / EnalaprilExperimentalAliskiren / Enalapril combination therapy-150 mg/10 mg titrated to 300 mg/ 10 mg film-coated tablets and administered orally.
Receives: Drug: Enalapril; Drug: Aliskiren
AliskirenExperimentalAliskiren monotherapy - 150 mg titrated to 300 mg film-coated tablets and administered orally.
Receives: Drug: Aliskiren
EnalaprilActive comparatorEnalapril monotherapy -10 mg film-coated tablet and administered orally.
Receives: Drug: Enalapril

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization

    Number of participants that had first occurrence of the composite endpoint, which is defined as either CV death or HF hospitalization due to HF.

    Measured: up to End of Study (78 months)

Secondary outcomes (2)

  1. Change From Baseline to Month 12 for the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score

    Change from baseline to Month 12 for the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score. KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. KCCQ clinical summary score is a composite assessment of physical limitations and total symptom scores. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

    Measured: Baseline, Month 12

  2. All Cause Death

    Number of patients - All-cause death. All-cause death is common in Heart Failure HF patients this measures how many patients had this event.

    Measured: up to end of study (78 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Mar 2009 (estimated)
  2. Study startMar 2009
  3. Primary completionOct 2015
  4. Study completionOct 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
7,064 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00853658
Sponsor's protocol ID
CSPP100F2301
Other IDs
2008-004104-31, 2008
Acronym
ATMOSPHERE
Status last verified
Oct 2016
First submitted
26 Feb 2009
Last updated
25 Nov 2016
Data monitoring committee
Yes

Publications

  • Patel-Murray NL, Zhang L, Claggett BL, Xu D, Serrano-Fernandez P, Healey M, Wandel S, Chen CW, Jacob J, Xu H, Turner GM, Chutkow W, Yates DP, O'Donnell CJ, Prescott MF, Lefkowitz M, Gimpelewicz CR, Beste MT, Zhao F, Gou L, Desai AS, Jhund PS, Packer M, Pfeffer MA, Redfield MM, Rouleau JL, Zannad F, Zile MR, McMurray JJV, Mendelson MM, Solomon SD, Cunningham JW. Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Proteomic Substudy. J Am Heart Assoc. 2024 Jul 2;13(13):e033544. doi: 10.1161/JAHA.123.033544. Epub 2024 Jun 21.

    PubMed 38904251

  • Kondo T, Dewan P, Anand IS, Desai AS, Packer M, Zile MR, Pfeffer MA, Solomon SD, Abraham WT, Shah SJ, Lam CSP, Jhund PS, McMurray JJV. Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification? Circulation. 2023 Aug 29;148(9):732-749. doi: 10.1161/CIRCULATIONAHA.122.063642. Epub 2023 Jun 27.

    PubMed 37366061

  • Shen L, Claggett BL, Jhund PS, Abraham WT, Desai AS, Dickstein K, Gong J, Kober LV, Lefkowitz MP, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, McMurray JJV. Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. Clin Res Cardiol. 2021 Aug;110(8):1334-1349. doi: 10.1007/s00392-021-01888-x. Epub 2021 Jun 8.

    PubMed 34101002

  • Wang GM, Li LJ, Tang WL, Wright JM. Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2020 Oct 22;10(10):CD012569. doi: 10.1002/14651858.CD012569.pub2.

    PubMed 33089502

  • Kristensen SL, Castagno D, Shen L, Jhund PS, Docherty KF, Rorth R, Abraham WT, Desai AS, Dickstein K, Rouleau JL, Zile MR, Swedberg K, Packer M, Solomon SD, Kober L, McMurray JJV; PARADIGM-HF and ATMOSPHERE Committees and Investigators.. Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. Eur J Heart Fail. 2020 Dec;22(12):2370-2379. doi: 10.1002/ejhf.1972. Epub 2020 Sep 14.

    PubMed 32720404

  • Docherty KF, Shen L, Castagno D, Petrie MC, Abraham WT, Bohm M, Desai AS, Dickstein K, Kober LV, Packer M, Rouleau JL, Solomon SD, Swedberg K, Vazir A, Zile MR, Jhund PS, McMurray JJV. Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. Eur J Heart Fail. 2020 Mar;22(3):528-538. doi: 10.1002/ejhf.1682. Epub 2019 Dec 17.

    PubMed 31849164

  • Dewan P, Rorth R, Raparelli V, Campbell RT, Shen L, Jhund PS, Petrie MC, Anand IS, Carson PE, Desai AS, Granger CB, Kober L, Komajda M, McKelvie RS, O'Meara E, Pfeffer MA, Pitt B, Solomon SD, Swedberg K, Zile MR, McMurray JJV. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2019 Dec;12(12):e006539. doi: 10.1161/CIRCHEARTFAILURE.119.006539. Epub 2019 Dec 9.

    PubMed 31813280

  • Shen L, Ramires F, Martinez F, Bodanese LC, Echeverria LE, Gomez EA, Abraham WT, Dickstein K, Kober L, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Jhund PS, Gimpelewicz CR, McMurray JJV; PARADIGM-HF and ATMOSPHERE Investigators and Committees. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circ Heart Fail. 2017 Nov;10(11):e004361. doi: 10.1161/CIRCHEARTFAILURE.117.004361.

    PubMed 29141857

  • Kristensen SL, Jhund PS, Mogensen UM, Rorth R, Abraham WT, Desai A, Dickstein K, Rouleau JL, Zile MR, Swedberg K, Packer M, Solomon SD, Kober L, McMurray JJV; PARADIGM-HF and ATMOSPHERE Committees and Investigators. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circ Heart Fail. 2017 Oct;10(10):e004409. doi: 10.1161/CIRCHEARTFAILURE.117.004409.

    PubMed 29018174

  • Kristensen SL, Mogensen UM, Tarnesby G, Gimpelewicz CR, Ali MA, Shao Q, Chiang Y, Jhund PS, Abraham WT, Dickstein K, McMurray JJV, Kober L. Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. Eur J Heart Fail. 2018 Jan;20(1):136-147. doi: 10.1002/ejhf.896. Epub 2017 Sep 25.

    PubMed 28948656

  • McMurray JJ, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM; ATMOSPHERE Committees Investigators. Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. N Engl J Med. 2016 Apr 21;374(16):1521-32. doi: 10.1056/NEJMoa1514859. Epub 2016 Apr 4.

    PubMed 27043774

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Enalapril and Aliskiren in people with Chronic Heart Failure, run by Novartis Pharmaceuticals at 806 sites in 44 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Nov 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 806 sites in Germany, United States, Italy, Japan, Russia and 39 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 25 Nov 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization (time frame: up to End of Study (78 months)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00853658, which also lists 11 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Nov 2016.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in